Bluejay Diagnostics, Inc. (BJDX)
NASDAQ: BJDX · Real-Time Price · USD
3.350
-0.210 (-5.90%)
At close: Jan 17, 2025, 4:00 PM
3.310
-0.040 (-1.19%)
After-hours: Jan 17, 2025, 5:53 PM EST
Bluejay Diagnostics Employees
Bluejay Diagnostics had 10 employees as of December 31, 2023. The number of employees decreased by 6 or -37.50% compared to the previous year.
Employees
10
Change (1Y)
-6
Growth (1Y)
-37.50%
Revenue / Employee
n/a
Profits / Employee
-$858,855
Market Cap
1.80M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 10 | -6 | -37.50% |
Dec 31, 2022 | 16 | 7 | 77.78% |
Dec 31, 2021 | 9 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
BJDX News
- 2 months ago - Bluejay Diagnostics Announces Reverse Stock Split - GlobeNewsWire
- 7 months ago - Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering - GlobeNewsWire
- 7 months ago - SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study) - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results - GlobeNewsWire
- 1 year ago - Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - GlobeNewsWire